Skip to main content
. Author manuscript; available in PMC: 2011 Aug 30.
Published in final edited form as: Int J Pharm. 2010 Jul 1;396(1-2):111–118. doi: 10.1016/j.ijpharm.2010.06.039

Fig. 1.

Fig. 1

Concentration-dependent inhibition of taurocholate uptake into ASBT-MDCK monolayers by (A) CDCA-lysine-niacin (●) and niacin (○) (B) CDCA-lysine-ketoprofen (●) and ketoprofen (○) for 10 min. Circles indicate observed data points, while the solid line indicates model fit. Taurocholate uptake into ASBT-MDCK cells was reduced significantly by both conjugates, where Ki was 12.9 μM for niacin prodrug and 15.6 μM for ketoprofen prodrug. Taurocholate uptake was not reduced by niacin or ketoprofen.